Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940761 | 0.92 | HTT (0.55) | ALDH1A1LMNAHTTPAX8MAPK1 | |
| SCHEMBL425317 | 0.83 | ALDH1A1 (0.71) | ALDH1A1LMNAHTTPAX8MAPK1 | |
| SCHEMBL5625835 | 0.82 | GAA (0.44) | ALDH1A1NPC1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL1481655 | 0.81 | KMT2A (0.59) | ALDH1A1LMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL2941971 | 0.81 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTNPC1KMT2A | |
| SCHEMBL29937859 | 0.81 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTNPC1KMT2A | |
| SCHEMBL5624371 | 0.79 | SIRT6 (0.58) | ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL29937396 | 0.78 | MAPT (0.51) | ALDH1A1LMNAHTTMAPK1NPC1 | |
| SCHEMBL77799 | 0.78 | ALDH1A1 (0.54) | ALDH1A1LMNAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL4458565 | 0.78 | MAPT (0.51) | ALDH1A1LMNAHTTMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | ALDH1A1 2861/4885LMNA 181/4885HTT 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.